-
10:17:48 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

GILD Stock News

10/19/21 8:30 AM
Nasdaq : GILD
covid-19
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
Gilead Sciences, Inc. today announced that the company will donate 100,000 vials of Veklury ® to help address the recent surge of COVID-19 cases in Indonesia and 3,000 vials of Veklury to help patients hospitalized with COVID-19 in Armenia. “As cases of COVID-19 surge again around the world, and the pandemic continues to affect the lives of so many, we remain...
RHEA-AI
neutral
10/18/21 7:30 AM
Nasdaq : GILD
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration approved a new low-dose tablet dosage form of Biktarvy ® for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. “Children living with HIV are in need of effective and accessible formulations of...
RHEA-AI
very positive
10/15/21 8:00 AM
Nasdaq : GILD
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for sacituzumab govitecan as monotherapy indicated for adult patients with unresectable or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least...
RHEA-AI
neutral
10/01/21 5:46 PM
Nasdaq : GILD
fda approval
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Kite, a Gilead Company, today announced the U.S. Food and Drug Administration has granted approval for Tecartus ® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Patients can access Tecartus through 109 authorized treatment centers across the U.S.. “Adults with ALL face a significantly poorer...
RHEA-AI
very positive
09/30/21 4:50 PM
Nasdaq : GILD
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
Kite, a Gilead Company, today announced that it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for Yescarta ® to expand its current indication to include the treatment of adults with relapsed or refractory large B-cell lymphoma in the second-line setting. The sBLA filing is based on data from the ZUMA-7...
RHEA-AI
neutral
09/27/21 4:35 PM
Nasdaq : GILD
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization
Gilead Sciences, Inc. today announced that Health Canada has approved Trodelvy ® for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior therapies, at least one of them for metastatic disease. Canada joins Australia, Great Britain, Switzerland, and the United...
RHEA-AI
neutral
09/22/21 9:01 AM
Nasdaq : GILD
covid-19
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Gilead Sciences, Inc. today announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury ® for intravenous use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. Enrollment for this trial was stopped prior to...
RHEA-AI
neutral
09/20/21 8:30 AM
Nasdaq : GILD
conferences
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
Gilead Sciences, Inc. today announced the upcoming presentation of new data from the company’ s virology research and development programs at the virtual IDWeek 2021 conference, taking place September 29– October 3. “In partnership with the infectious disease community, we continue to monitor and respond to the devastating global viral pandemic, while...
RHEA-AI
negative
09/16/21 7:00 AM
Nasdaq : GILD
clinical trial
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Gilead Sciences, Inc. today announced new data from the Phase 3 ASCENT study of Trodelvy ® in patients with relapsed or refractory metastatic triple-negative breast cancer who received two or more prior systemic therapies, at least one of them for metastatic disease. “In TNBC, limited treatment options and poor survival outcomes are compounded by a...
RHEA-AI
neutral